P-034 Real world Experience of Talquetamab in Relapsed Refractory Myeloma, First Report From the IMWG Consortium

Murali Janakiram; Carlyn Tan; Rakesh Popat; Efstathios Kastritis; Joaquín Martínez‐López; Tala Shekarkhand; Radhika Bansal; Andre De Menezes Silva Corraes; M. Puerta; Adolfo Jesús Sáez Marín; Myo Htut; Despina Fotiou; Meletios A Dimopoulos; Arnab Chowdhury; Shaji Kumar; T. John Martin; Amrita Krishnan

doi:10.1016/s2152-2650(24)01937-2

Related publications

Article2024

Real-World Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with Teclistamab and Talquetamab; A Multicenter Analysis from the Greek Myeloma Study Group

Ioannis Ntanasis‐Stathopoulos, Eirini Katodrytou, Evdoxia Hatjiharissi, Emmanouil Spanoudakis, Vasiliki Douka, Despina Fotiou, Vasiliki Labropoulou, Dimitra Dalampira, Vasiliki Spiliopoulou, Theodosia Papadopoulou, Dimitrios Christoulas, Panagiotis Malandrakis, Anthi Bouchla, Vasiliki Pappa, Efstathios Kastritis, Evangelos Terpos, Meletios A Dimopoulos, Maria Gavriatopoulou

Article2024

Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee

Carlyn Tan, Sireesha Asoori, David Nemirovsky, Andriy Derkach, Larissa Brunaldi, Rakesh Popat, Chris Lau, Efstathios Kastritis, Joaquín Martínez‐López, Radhika Bansal, Andre De Menezes Silva Corraes, Saurabh Chhabra, Ricardo Parrondo, Sikander Ailawadhi, Despina Fotiou, Meletios A Dimopoulos, Kwee Yong, Catriona Mactier, Magdalena Corona, Adolfo Jesús Sáez Marín, Hira Mian, Saad Z. Usmani,

Article2021

Real-World Treatment of Patients With Relapsed/Refractory Myeloma

Ioannis Ntanasis‐Stathopoulos, Maria Gavriatopoulou, Evangelos Terpos, Meletios A Dimopoulos

Article2019

Real World Treatment of Patients with Relapsed/Refractory Myeloma

Meletios A Dimopoulos, Ioannis Ntanasis‐Stathopoulos, Evangelos Terpos

Article2024

Comparative Effectiveness of Linvoseltamab Versus Current Real-World Standard of Care Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Treated at IMWG Sites

Shaji Kumar, Sundar Jagannath, Katja Weisel, Laura Rosiñol Dachs, Meletios A Dimopoulos, David S. Siegel, Jorge Monge, Xavier Leleu, Juan Du, Javier de la Rubia, Jae Hoon Lee, María-Victoria Mateos, Alessandro Gozzetti, Dominik Dytfeld, Enrique M. Ocio, Joan Bladé, Shuji Ozaki, Madhu Nagaraj, Rafla Hassan, Jeannette Green, Glenn S. Kroog,

P-034 Real world Experience of Talquetamab in Relapsed Refractory Myeloma, First Report From the IMWG Consortium

Discussion(0)

Related publications

Real-World Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with Teclistamab and Talquetamab; A Multicenter Analysis from the Greek Myeloma Study Group

Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee

Real-World Treatment of Patients With Relapsed/Refractory Myeloma

Real World Treatment of Patients with Relapsed/Refractory Myeloma

Comparative Effectiveness of Linvoseltamab Versus Current Real-World Standard of Care Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Treated at IMWG Sites